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ABSTRACT
Objective To evaluate the health-economic costs and 
beneits of a guided eHealth intervention (E-health module 
embedded in Collaborative Occupational healthcare (ECO)) 
encouraging sick-listed employees to a faster return to 
work.
Design A two-armed cluster randomised trial with 
occupational physicians (OPs) (n=62), clustered and 
randomised by region into an experimental and a control 
group, to conduct a health-economic investment appraisal. 
Online self-reported data were collected from employees 
at baseline, after 3, 6, 9 and 12 months.
Setting Occupational health care in the Netherlands.
Participants Employees from small-sized and medium-
sized companies (≥18 years), sick-listed between 4 and 
26 weeks with (symptoms of) common mental disorders 
visiting their OP.
Interventions In the intervention group, employees 
(N=131) received an eHealth module aimed at changing 
cognitions regarding return to work, while OPs were 
supported by a decision aid for treatment and referral 
options. Employees in the control condition (N=89) 
received usual sickness guidance.
Outcomes Measures Net beneits and return on 
investment based on absenteeism, presenteeism, health 
care use and quality-adjusted life years (QALYs) gained.
Results From the employer’s perspective, the incremental 
net beneits were €3187 per employee over a single year, 
representing a return of investment of €11 per invested 
Euro, with a break-even point at 6 months. The economic 
case was also favourable from the employee’s perspective, 
partly because of QALY health gains. The intervention 
was costing €234 per employee from a health service 
inancier’s perspective. The incremental net beneits from 
a social perspective were €4210. This amount dropped to 
€3559 in the sensitivity analysis trimming the 5% highest 
costs.
Conclusions The data suggest that the ECO intervention 
offers good value for money for virtually all stakeholders 
involved, because initial investments were more than 
recouped within a single year. The sometimes wide 95% 
CIs suggest that the costs and beneits are not always 
very precise estimates and real beneits could vary 
considerably.
Trial Registration NTR2108; Results.
INTRODUCTION
Long-term sickness absence has a significant 
economic impact, largely due to the substan-
tial productivity losses.1 2 Mental disorders 
are a leading cause of sickness absence,3–6 
which is not without economic ramifications.7 
Common mental disorders, specifically 
depression and anxiety, are the most preva-
lent in the workforce.8
For the treatment of common mental disor-
ders, a range of psychological and pharma-
ceutical interventions have been shown to 
be effective and cost-effective.9 10 However, 
symptomatic recovery does not automatically 
reduce sickness absence.10–12 To improve 
occupational outcomes, it is also important 
to pay attention to return to work during 
treatment.
In the Netherlands, treatment and sick-
ness certification are separated from each 
other in social security legislation. Occupa-
tional physicians (OPs) play a central role in 
the sickness guidance of workers by making 
a problem analysis and giving advice on a 
return to work plan, whereas treatment is 
provided by the mental health sector. The 
legislation was introduced to protect the 
worker’s privacy and relationship with the 
curative physician.13 14 A guideline has been 
developed to suggest directions to OPs to 
Strengths and limitations of this study
 Ź This study adds to the few available studies that 
present a trial-based investment appraisal of the 
economic costs and beneits of a return to work 
intervention for sick-listed employees.
 Ź The trial was only powered to test a difference 
in sickness absence duration and not for testing 
economic hypotheses.
 Ź The follow-up time is limited to 12 months.
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better assist employees with mental health problems in 
the return to work process. According to this guideline, 
the OPs need to closely monitor both the mental health 
problems and the level of functioning. When recovery 
is slow or hampered, they can consult or refer to a 
psychiatrist, a psychologist or a social worker.15 A study 
of Rebergen and colleagues suggested that better adher-
ence to the guideline is associated with earlier return to 
work.16 However, in practice, adherence appears to be far 
from optimal,17 18 and there is often a lack of cooperation 
between the OPs and treatment providers in the mental 
health sector. Several attempts have been made to bridge 
this gap. One study about the effect of psychiatric consul-
tation for OPs assisting sick-listed employees did provide 
results in terms of earlier return to work.19 However, this 
study was small. Another study evaluating active treat-
ment by an OP within a collaborative care arrangement 
did improve depressive symptoms, but failed to speed 
up return to work.20 It appeared that OPs need support 
in helping sick-listed employees change their attitude 
towards resuming work and that OPs should monitor 
symptom improvement and work performance in a more 
systematic manner.
To overcome these problems and to better manage the 
return to work of sick-listed employees with (symptoms 
of) common mental disorders, the ‘E-health module 
embedded in Collaborative Occupational healthcare’ 
(ECO) intervention was developed. The ECO interven-
tion was designed to promote return to work by improving 
work functioning in employees, providing a decision aid 
for the OP who gives guidance to the employee, and by 
including the opportunity for psychiatric consultation to 
the OP.21
The results of a recent trial showed that ECO led to an 
earlier return to work than usual care (mean duration of 
50 days in the ECO group vs 77 days in the care as usual 
(CAU) group) and higher remission rates of common 
mental disorder after 9 months in a group of sick-listed 
employees with (symptoms of) mental disorders.22
Taking the economic perspective, we expect that 
the ECO intervention is cost-effective as seen from the 
employer’s viewpoint because ECO is a low-cost self-help 
intervention with a limited amount of support from the 
OP and appears to be effective in reducing absenteeism. 
There is less certainty how cost-effective the intervention 
would be as seen from the perspective of the sick-listed 
employees and the healthcare financier (ie, healthcare 
insurance company in the Dutch context). Therefore, 
this study conducts a cost–benefit analysis of the ECO 
intervention from all three stakeholders’ viewpoints, 
and combines these in an overarching societal perspec-
tive. These analyses are important because very few trial-
based economic evaluations have been conducted with 
regard to return-to-work interventions for sick-listed 
employees with (symptoms of) common mental disor-
ders.12 23
METHOD
Study design
The ECO study was designed as a two-armed cluster 
randomised controlled trial, with randomisation at the 
level of the OP. OPs were either randomised to usual care 
alone or usual care plus the ECO intervention. The Neth-
erlands Organisation for Health Research and Develop-
ment funded the study (grant number 171002403 ZonMw 
Doelmatigheid) together with Achmea, a Dutch insur-
ance company. The Medical Ethics Committee of the 
University Medical Center Utrecht approved the study 
protocol in 2011, and the trial was registered at the Neth-
erlands Trial Register under number 2108. The design of 
the study is described in detail elsewhere.21 22 Here, we 
provide a brief summary of the main characteristics and 
focus on the economic aspects.
Randomisation
To prevent contamination, cluster randomisation took 
place at the area level of the OPs working in the same 
region across a total of 12 regions. An independent statis-
tician randomised six regions to the ECO condition and 
the remainder to the control condition using comput-
er-generated randomisation. Since the OPs had to offer 
the intervention, they could not be blinded for randomi-
sation. The researchers and participants were informed 
about the allocation after the randomisation procedure.
Participants
Participants were recruited from July 2011 to January 2013 
from all-cause sick-listed employees working at small-sized 
and medium-sized companies in the Netherlands who 
visited an OP. To be eligible for inclusion, the employees 
had to be at least 18 years of age and on sickness absence 
between 4 and 26 weeks. This time window was chosen to 
avoid including employees with spontaneous recovery and 
to increase the probability of employees ever returning to 
work.24 In addition, the employees needed to have a score 
≥10 on either the depression or the somatisation scale of 
the Patient Health Questionnaire,25 26 or the Generalised 
Anxiety Disorder questionnaire.27 Exclusion criteria were 
(1) poor command of the Dutch language, (2) preg-
nancy, (3) not having access to the internet and (4) being 
involved in a legal action against the employer.
Procedure
Initially, an independent statistician randomised 12 
regions to either CAU (six regions with 30 OPs) or ECO 
(six regions with 32 OPs) by using a computer algo-
rithm. Within the cluster of CAU regions, 5875 sick-
listed employees were screened for eligibility resulting 
in 326 screen-positives. In the cluster of ECO regions, 
537 screen-positives were obtained from 8740 sick-listed 
employees. Of these, 89 consenting participants received 
sickness guidance from OPs who were randomised to 
CAU and 131 participants from OPs in the ECO cluster. 
The unequal distribution of participants over the condi-
tions was due to the cluster randomisation of the OPs. 
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Participants received measurements at baseline and at 3, 
6, 9 and 12 months post baseline. Dropout occurred in 
both conditions (see figure 1).
Intervention
ECO consists of two components: (1) the eHealth module 
Return@Work for the employee and (2) an email-based 
decision aid to support the OP. Return@Work is aimed at 
improving the self-efficacy of employees and promoting 
the employee’s intention to return to work. Recent studies 
have shown that these factors are predictors of actual work 
resumption.28–30 The decision aid provides the OPs with 
advice regarding treatment and referral options based on 
the employee’s outcome monitoring in Return@Work.
The eHealth module starts with an assessment ques-
tionnaire. Depending on the results of the questionnaire 
regarding symptoms and cognitions about return to work 
of the individual employee, Return@Work presented 
specific modules and sessions. As a consequence, the 
amount of modules and sessions offered to the employees 
differed. In total, Return@Work included five modules 
composed of 16 sessions, covering: (1) psychoeducation, 
(2) cognitions regarding return to work while having 
symptoms (based on principles of cognitive behavioural 
therapy), (3) problem solving skills, (4) pain and fatigue 
management and reactivation and (5) relapse prevention. 
The employees went through the modules independently, 
but had the possibility to discuss Return@Work modules 
and assignments with the OP. The OPs were requested 
to inquire about the employee’s progress in the eHealth 
module and to provide support if necessary during their 
regular face-to-face contacts with the employee. Periodic 
visits between the employee and the OP are part of the 
guidelines of the Netherlands Society of Occupational 
Medicine (NVAB),15 to which all OPs were required to 
adhere.
Besides the modules, Return@Work also contained 
a monitor of functioning and symptoms on a regular 
basis. This monitor was used for the second component 
of ECO, a decision aid to support OPs in the sickness 
guidance of employees. Based on the outcomes of the 
monitor in Return@Work, the OPs received automated 
email messages with advice for next steps in collaborative 
care. In addition, the decision aid gave OPs the option 
to consult a psychiatrist in case insufficient progress was 
made. The OPs in the experimental condition received a 
4-hour training about ECO.
In the control condition, the employees received usual 
sickness guidance. The guidelines of the NVAB were used 
as a protocol.15 As there is a lack of adherence to the 
guidelines,17 18 actual care was assessed with a question-
naire by all of the participating employees.
Outcome measures
Participants filled in the Medical Technology Assess-
ment Cost Questionnaire for Psychiatry (TiC-P),31 that 
among healthcare use also measures absenteeism from 
work, which is the main outcome variable of this study. 
The TiC-P is based on self-report, and to cross-check the 
number of work days lost to absenteeism, we compared the 
self-reports with administrative data (see Sensitivity anal-
ysis section below). Total follow-up time was 12 months 
with measurements at baseline and after 3, 6, 9 and 12 
months. Finally, health gains in terms of quality-adjusted 
life years (QALYs) were assessed using the 3-level version 
of the EuroQoL-5D,32 with the Dutch tariff.33
Resource use and costing
Cost data were collected using the TiC-P, including (1) 
direct medical costs, including the costs of medication, (2) 
direct non-medical costs (patients’ out-of-pocket costs for 
trips to health services), (3) costs stemming from produc-
tivity losses owing to absenteeism and presenteeism and 
(4) costs that occurred in the domestic realm (help for 
housekeeping from family, friends or hired people). Stan-
dard costs, expressed in euro (€), were indexed for the 
reference year 2011 using the consumer price index from 
Statistics Netherlands. Costs were not discounted because 
the follow-up period did not exceed 1 year.
Computation of costs
The set costs of the ECO intervention were €300 per user, 
which is its current (post trial) rate. Direct medical costs 
were limited to mental health service use. The medical 
costs were computed by multiplying the number of health 
service units (sessions, visits, hospital days) with their stan-
dard full economic cost price.34 Only medication costs for 
mental problems were included in the economic analysis. 
For every type of drug (eg, antidepressants, benzodiaz-
epines, antipsychotics, hypnotics), an average cost price 
was calculated based on the cost prices per standard daily 
dose of three drugs most often prescribed to the partici-
pants as reported in the Pharmaceutical Compass,35 while 
taking into account the GP’s prescription costs, the phar-
macist’s dispensing costs and the pharmacist’s claw back 
as per the guideline for cost computations in healthcare.34
The direct non-medical costs consisted of the travel 
costs that participants had to make to visit OPs and health 
services. These costs were calculated as the average 
distance to the specific health service provider multiplied 
by the costs per km (€0.21) plus parking costs (€3.11) 
per hour. To the direct non-medical costs, we added the 
costs of (informal) caregivers (eg, family and friends) 
due to the employee’s reduced functionality at home, 
computed by multiplying the number of hours by €12.96.
In the Netherlands, QALY health gains are valued 
between €20 000 and €80 000  per QALY.36 We used the 
lower bound of €20 000 to conduct our analysis under 
conservative assumptions.
Productivity losses comprised the costs of lost work days 
due to absenteeism and the costs of inefficiency while at 
work (presenteeism). We used the human capital method 
to value the productivity costs.37 In the case of absen-
teeism, this method multiplies the number of days absent 
by the gender and age-specific average gross wages per 
employee, as per the Dutch guideline for health economic 
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Figure 1 Flowchart of the participants. CAU, care as usual. ECO, E-health module embedded in Collaborative Occupational 
health care.
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evaluation.34 To assess the costs of presenteeism, we used 
the number of days actually worked when ill multiplied 
by a self-reported inefficiency score. This score ranged 
from 0 (as effective as in good health) to 1 (totally inef-
fective). Again, the gender and age-specific average gross 
wages were used to compute the costs of presenteeism. To 
illustrate, if an employee reported an inefficiency score of 
0.50 for 7 working days, then we assumed that 3.5 working 
days have been lost due to presenteeism.
Analyses
Following recommendations from the Consolidated 
Standards of Reporting Trials (CONSORT) and Consol-
idated Health Economic Evaluation Reporting Stan-
dards (CHEERS) statements,38–40 analyses were conducted 
in agreement with the intention-to-treat principle. There-
fore, all participants as randomised were retained in 
the analysis, and missing observations due to dropout 
were imputed. For imputation, we used both the estima-
tion-maximisation (EM) algorithm as implemented in 
SPSS for the main analysis and regression imputation (RI) 
as implemented in Stata for the sensitivity analysis (see 
below). In both imputation strategies, we used predictors 
of outcomes (costs and QALYs) and predictors of dropout 
(age, gender, partner status, country of birth, number of 
work loss days). Predictors of the outcomes were included 
to increase precision in the imputed values, predictors of 
dropout were incorporated to tackle selection bias, if any, 
and to meet the missing at random (MAR) assumption 
underlying most imputation techniques.
The economic evaluation was conducted as an incre-
mental cost–benefit analysis because the primary outcome 
(duration of sick leave) could directly be expressed in 
terms of monetary benefits. The costs and benefits were 
calculated at baseline, 3, 6, 9 and 12 months in the ECO 
and CAU conditions. The costs in the intermediate 
months were linearly interpolated. This allowed mapping 
the monthly cash flows of costs and benefits over the 
full 12-month period. The cash flows were computed 
from four perspectives: (1) the employer’s perspective 
focussing on the net benefits from greater productivity 
via lesser absenteeism and lesser presenteeism; (2) the 
healthcare payer’s perspective (in the Netherlands: 
healthcare insurers) focussing on the direct medical costs 
due to health service use, including the costs of medica-
tion, (3) the employee’s perspective focussing on QALY 
health gains, fewer out-of-pockets costs and less informal 
care from family members or friends. Finally, we included 
the societal perspective (4), including all costs and bene-
fits, regardless of who incurs costs or receives benefits.
The monthly cash flows were used to compute the 
cumulative costs and cumulative monetary benefits 
over the full 12 months. Incremental costs, incremental 
benefits and incremental net benefits were obtained 
by comparing ECO intervention with CAU. These are 
the main outcomes of the economic analysis alongside 
metrics such as the break-even point and the return on 
investment (ROI).
For assessing the incremental net benefits, we relied 
on non-parametric bootstrapping (2500 replications) 
since costs are non-normally distributed. Statistics such as 
mean costs, 95% CIs, SEs and p values are all based on 
non-parametric bootstrapping to increase the robustness 
of our findings. The data were analysed in SPSS (V.22) 
and Stata (V.13.1).
Sensitivity analysis
The main analysis (using the overarching societal perspec-
tive and based on EM imputation) was repeated three 
times in a series of sensitivity analyses. First, the analysis 
was conducted again, but now, based on RI to assess the 
robustness of the findings under a different imputation 
technique. Second, we crosschecked the self-reported 
absenteeism against administrative data derived from 
the registers of the occupational health service or the 
employer because the main analysis was based on self-re-
ports and some recall bias (under-reporting) could have 
occurred. Finally, we recalculated the incremental net 
benefits after trimming the highest 5% of total cumula-
tive costs per employee because the participants with the 
extremely high costs were only a small minority but may 
have exercised a disproportional influence on the cost 
estimates and pushed outcomes to a more favourable 
outcomes for the ECO intervention. By excluding these 
participants, primarily from the CAU condition, the net 
benefits were re-estimated but now under conservative 
assumptions.
RESULTS
Sample characteristics and baseline costs
Baseline characteristics of the sample (including base-
line costs) are presented in table 1. The mean age of 
the 220 participants was 44 years and 59% was women. 
No important differences were observed at baseline in 
demographic characteristics and quality of life, but base-
line costs were somewhat higher in the ECO condition, 
suggesting that the ECO group had a slightly disadvanta-
geous start. We will return to this issue in the Discussion. 
As described by Volker and colleagues,22 job characteris-
tics and sickness absence duration at baseline were also 
comparable between the intervention condition and 
control condition, indicating that the randomisation was 
generally well balanced.
Loss to follow-up
The measurements at 3, 6, 9 and 12 months were 
completed by 155 (70.5%), 157 (71.4%), 134 (60.9%) and 
128 (58.2%) of the participants. The dropout rate over 
the 12-month trial period was higher in the ECO condi-
tion (45.0%) than the control condition (37.1%), but this 
difference was not statistically significant (χ2=1.38; df=1; 
p=0.240). As indicated, we looked for variables that predict 
dropout and included these as predictors in the EM and 
RI imputations. This was done to counter selection bias 
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(if any) and to better meet the MAR assumption under-
pinning the imputation strategies.
On the topic of treatment adherence, 90 of the 131 
participants in the ECO condition (69%) finished the 
introduction and started with the intervention. These 
participants had a mean number of total log-ins of 7.8. 
Forty per cent (36/90) completed at least half of the 
modules and 23% (21/90) finished at least 70% of the 
prescribed number of sessions.22
Costs and QALYs at 3, 6, 9 and 12 months
The next step of the cost–benefit analyses was to ascertain 
costs and quality of life at the follow-up measurements 
(table 2). Cost differences were highest for absenteeism. 
At 12 months, all the cost differences were statistically 
significant and in favour of the ECO condition. The total 
costs difference at the 12-month follow-up amounted to 
€919 (SE=205; z=4.48; p<0.001), mainly due to reduced 
absenteeism.
Cost–benefit analysis: employer’s perspective
For the employer’s perspective, only the intervention 
costs and costs stemming from absenteeism and presen-
teeism were included, thus assuming that the employer 
would be interested to know the pay out of this invest-
ment when paying for the intervention. Cumulated over 
the 12-month period, the incremental benefits were 
€3487 in favour of the ECO condition (Bootstrapped 
95% CI −418 to 7390; SE=1992; z=1.75; p=0.080), which 
was mainly due to a larger reduction in absenteeism over 
12 months compared with CAU (bootstrapped M=4291; 
95% CI 2908 to 8292; SE=2041; z=2.10; p=0.036). Next, 
we calculated incremental net benefits by subtracting 
the intervention costs (€300) from the incremental 
benefits. As shown in table 3, the incremental net 
benefits over 12 months were €3187 per employee in 
favour of the ECO condition, but there is significant 
uncertainty in the estimate (bootstrapped 95% CI −656 
to 7029; SE=1961; z=1.63; p=0.104). We return to this 
issue in the Discussion. The break-even point for the 
employer, the moment in time where the investment 
of €300 is recouped, is around 6 months. The ROI is 
Table 2 Average monthly costs in the care as usual (CAU) 
and the ECO intervention group at 3, 6, and 9 months (in 
2011 Euro)*†
3 months 6 months 9 months 12 months
Direct medical costs
  CAU 474 321 383 296
  ECO 463 476 333 148
  Cost 
difference 11 −155 50 148
Direct non-medical costs
  CAU 135 74 102 98
  ECO 104 89 67 45
  Cost 
difference 31 −15 35 53
Productivity losses
Absenteeism
  CAU 2120 1699 1276 1118
  ECO 1887 1264 725 572
  Cost 
difference 233 435 551 546
Presenteeism
  CAU 166 233 269 493
  ECO 357 408 322 325
  Cost 
difference −191 −175 −53 168
Total costs
  CAU 2895 2328 2029 2005
  ECO 2811 2238 1446 1090
  Cost 
difference 84 90 583 915
Quality of life (utility)
  CAU 0.65 0.68 0.68 0.73
  ECO 0.65 0.72 0.76 0.77
  Difference 
in utilities 0 0.04 0.08 0.04
*Between-group differences in italics are statistically signiicant 
at p<0.05.
†Numbers may not add due to rounding.
ECO, E-health module embedded in Collaborative 
Occupational healthcare.
Table 1 Baseline characteristics in the care as usual (CAU) 
and the ECO intervention group
CAU (n=89) ECO (n=131)
Age, mean (SD) 45.5 (10.7) 43.3 (9.5)
Female, N (%) 53 (59.6) 77 (58.8)
Married/living together, N (%) 62 (69.7) 91 (69.5)
Educational level, N (%)
  Low 32 (36.0) 48 (36.6)
  Average 31 (34.8) 47 (35.9)
  High 26 (29.2) 36 (27.5)
Country of birth: The Netherlands, 
N (%)
83 (93.3) 123 (93.9)
Direct medical costs, mean (SD) 645 (58) 602 (49)
Direct non-medical costs, mean 
(SD)
35 (2) 33 (2)
Absenteeism, mean (SD) 2850 (146) 3078 (125)
Presenteeism, mean (SD) 34 (16) 20 (14)
Costs in the domestic realm, 
mean (SD)
143 (26) 133 (20)
Medication, mean (SD) 8 (2) 12 (3)
Total costs, mean (SD) 3716 (154) 3879 (141)
Quality of life, mean (SD) 0.57 (0.027) 0.54 (0.024)
ECO, E-health module embedded in Collaborative Occupational 
healthcare.
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3187/300=10.62, indicating that for every euro invested, 
the pay-out is €10.6.
Cost–benefit analysis: healthcare payer’s perspective
For the perspective of the healthcare financier, we looked 
at the direct medical costs including the costs for medica-
tion. We computed the monthly cash flows and compared 
these between the ECO and CAU conditions as before. 
The cumulative costs over 12 months were more or less 
the same for each condition with a small difference of 
€66 in favour of the ECO condition. Assuming that the 
health insurer would pay for the intervention, the inter-
vention costs of €300 have to be subtracted from these 
benefits in order to obtain the net benefits. This gener-
ated a negative value of €234, implying that the ECO 
intervention is not cost saving from a healthcare insurer’s 
perspective (bootstrapped 95% CI −1379 to 911; SE=584; 
z=−0.40; p=0.689).
Cost–benefit analysis: employee’s perspective
Employee’s costs and benefits included direct non-med-
ical costs (ie, the patient’s out-of-pocket costs and costs in 
the domestic realm) and QALY health gains. Cumulated 
over 12 months, the incremental benefits for the ECO 
group were €262 regarding non-medical costs and €696 
due to QALY gains (0.035*€20 000). The incremental 
net benefits were €958–€300=658 (bootstrapped 95% CI 
2901 to 025; SE=187; z=3.51; p=0.000). The break-even 
point occurred at 8 months and the ROI was 658/300=2.2.
Cost–benefit analysis: societal perspective
For the societal perspective, we included the costs and 
benefits of all stakeholders. The difference between 
conditions of the cumulative benefits was €29 893–€25 
383=€4510 in favour of the intervention condition (boot-
strapped 95% CI 103 to 8918; SE=2249; z=2.01 p=0.045). 
Subtraction of the intervention costs of €300 yielded 
incremental net benefits from a social perspective of 
€4210 (bootstrapped 95% CI −259 to 8674; SE=22 77; 
z=1.85; p=0.064). Break-even was achieved at 7 months 
and the ROI was 4210/300=14.0.
Sensitivity analyses
For the main analysis, we used EM imputation; now, we 
recomputed the estimates under RI. Taking the societal 
perspective, the incremental net benefits became €4093 
(bootstrapped 95% CI −2798 to 465; SE=2231; z=1.83; 
p=0.067) and the ROI was 4093/300=13.6, which is close 
to the EM-based analysis (see table 4).
The incremental net benefits in the main analyses were 
dominated by the costs offsets due to reduced absen-
teeism, but these were based on self-reported data. Cross-
checking the self-reported data against administrative 
data derived from the registers of the occupational health 
service or employer showed that the estimates for days 
absent were lower in the analysis based on self-report data 
than on administrative data (72 work days absent based on 
self-reported data vs an average of 102 work days absent 
based on administrative data). When basing the analysis T
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on administrative data, the total cumulative incremental 
net benefits became €5316 (bootstrapped 95% CI −2590 
to 13 222; SE=4034; z=1.32; p=0.188), which is higher by 
a factor 1.3 than the corresponding estimate presented 
in the main analysis. The main analysis thus represents a 
safer (lower) estimate.
Finally, we repeated the main analysis by replacing the 
total costs of the respondents with the top 5% highest total 
costs due to absenteeism by the highest amount witnessed 
in the other 95% respondents. The top 5% outliers were 
mainly situated in the CAU condition, raising the average 
costs for this group. The incremental net-benefits based 
on the trimmed costs dropped from €4210 to €3559 (SE 
95% CI= −6117,729; SE=2128; z=1.67; p=0.094), which 
can be regarded as a more conservative lower bound.
DISCUSSION
Principal findings
This study was set out to evaluate the cost-effectiveness 
of an intervention that encourages sick-listed employees 
with (symptoms of) common mental disorders to make 
an early return to their work. The economic evaluation 
was conducted as an incremental cost–benefit analysis 
and reports on the incremental cost to benefit ratio, 
the return on investment, the break-even point and the 
incremental monetary net benefits, as customarily seen in 
business cases and investment appraisals. These metrics 
were computed from various perspectives: the perspective 
of the employer, the employee, the healthcare financier 
and society. The main findings can now be summarised 
as follows:
 Ź Taking the employer’s perspective, the focus of the 
economic evaluation was placed on the intervention 
costs and changes in productivity owing to changes 
in absenteeism and presenteeism. Assuming that the 
employer would make the investment in the ECO 
intervention of €300 per employee, the incremental 
net benefits were €3187 per employee over a year. 
This was equivalent to a ROI of €11 per invested Euro. 
Benefits largely stemmed from reduced absenteeism 
and exceeded the investment costs after 6 months.
 Ź From the perspective of the healthcare payer, the 
incremental net benefits were negative, amounting to 
additional costs of €234 per employee on average.
 Ź As seen from the employee, the net benefits, including 
the value of the employee’s QALY health gains, 
exceeded the costs by €658.
 Ź From the societal perspective, the initial investment 
was also more than recouped. Considering all costs 
and benefits, the incremental net benefits were 
€4210, with a break-even point at 7 months. Every 
euro invested yielded €14. Trimming the 5% highest 
costs, mostly from the care as usual condition, reduced 
the incremental net benefits to €3559.
Limitations
This study has several limitations, which are reported and 
discussed here.
 Ź First, cost data are often non-normally distributed with 
some people generating very high costs. This results 
in large SD in the cost estimates and less precise esti-
mates of average costs. In such a context, it would 
require a very large sample size to power the trial for 
testing economic hypotheses. However, our study was 
only powered to test a difference in sickness absence 
duration. As a consequence, the wide 95% CIs indi-
cate that the cost estimates are subject to much uncer-
tainty. More specifically, trimming the highest 5% of 
the costs in one of our sensitivity analysis showed that 
the incremental net benefits became €3559, which is 
85% of the original estimate of €4210. This suggests 
that our study needs replication, preferably in a larger 
study.
 Ź Second, loss-to follow-up was substantial. To handle 
dropout, missing data were imputed using EM. To 
ascertain the robustness of our findings, we also used 
RI. With RI, we arrived at similar conclusions: €4093 
(vs €4210 under EM), attesting to the robustness in 
our findings. Nonetheless, selection bias introduced 
by (selective) dropout cannot be ruled out completely 
and could have influenced the outcomes that we 
obtained.
 Ź Third, costs at baseline were higher in the ECO condi-
tion. We could have adjusted for the baseline differ-
ences, but this would most likely have led to even 
better outcomes in favour of the ECO condition. 
Ignoring the baseline differences has therefore put 
our main analyses on a more conservative footing.
 Ź Fourth, the main driver of costs and benefits was 
absenteeism and, in the main analysis, these were 
based on self-report. This may have introduced some 
recall bias, but self-reports of absenteeism usually 
involve under-reporting, thus leading to conserva-
tive outcomes. Still, we crosschecked the self-reports 
against administrative data from the registers of the 
Table 4 Incremental net beneit and return on investment from societal perspective for base case and sensitivity analyses (in 
2011 Euro)
Incremental net benefit Return on investment
Base case analysis 4210 (−259 to 8674) 14.0
Sensitivity analysis regression imputation 4093 (−279 to 8465) 13.6
Sensitivity analysis administrative data 5316 (−2590 to 13,222) 17.7
Sensitivity analysis trimming highest 5% 3559 (−611 to 7729) 11.9
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occupational health service and the employer. As 
expected, the benefits were lower when based on 
self-reports than on administrative data.
 Ź Fifth, it should be noted that the cost–benefit anal-
ysis did not include the future costs of implementing 
the ECO intervention on a wider scale. As the main 
component is a low cost self-help intervention 
(Return@Work) and the training of OPs only lasts a 
few hours, the implementation costs are expected to 
be low, but should be considered when the interven-
tion is disseminated on a wider scale.
 Ź Finally, the follow-up time is limited to 12 months. 
We do not know what the net benefits would be over 
a longer time span. However, costs differences were 
highest in the last months. This may imply that a 
longer follow-up period would have seen more profit-
able outcomes.
Results in context
Reviews about the effectiveness of psychological return 
to work interventions for employees with mental health 
problems show mixed outcomes in reducing sickness 
absence and promoting an earlier return to work.12 23 
Moreover, only a few of the reviewed studies that appeared 
to be effective report a full economic evaluation. Of 
these, none evaluated a guided eHealth intervention for 
return to work. One study that is somewhat comparable 
with our study is from Schene and colleagues. Schene et 
al describe the economic evaluation of an intervention 
for employees with major depression, who were sick-listed 
between 10 weeks and 2 years.41 The experimental condi-
tion received occupational therapy in addition to usual 
outpatient treatment for depression. Their intervention 
increased the number of hours worked accumulating in 
a median economic gain of US$4000–5000 per patient 
per year, which is in line with our findings regarding the 
reduction in absenteeism. The study of Schene et al was 
smaller (n=62), was directed at a more severely depressed 
population and the intervention was not delivered online 
but as an intensive face-to-face therapy consisting of 24 
group sessions and 15 individual sessions.
Lerner and colleagues evaluated a brief telephonic 
programme to improve work functioning for employees 
with major depressive disorder or dysthymia with an 
at-work productivity loss of at least 5% in the past 2 weeks.42 
Compared with usual care, annualised cost savings aver-
aged at $6042 per participant, but these savings were 
extrapolated from a shorter (4 months) follow-up. These 
cost savings are higher than the cost-savings observed in 
our study. Nonetheless, Lerner’s et al extrapolation from 
4 to 12 months might have overstated the savings if the 
treatment effect was not sustained.
Arends and colleagues evaluated the costs and bene-
fits of a problem-solving intervention provided by OPs 
to prevent recurrent sickness absence in workers with 
common mental disorders.43Compared with care as usual, 
the intervention was more effective but also more expen-
sive. From an employer’s perspective, the intervention 
showed no economic benefits, which is in contrast to our 
study.
Noben and colleagues conducted a cost–benefit 
analysis from the employer’s perspective of a preven-
tive intervention in the work setting among nurses with 
an elevated risk of mental complaints.44 The authors 
concluded that the intervention was a good investment 
as the net benefits (stemming from reduced absen-
teeism and presenteeism) were positive (€651) and the 
ROI was €11 per Euro spent. This return on investment 
is comparable with ours.
In contrast to Noben and colleagues and several other 
studies,45 we found negative results for presenteeism in 
the short run (first 9 months), but these were alleviated in 
the longer run (at the end of the year). An explanation 
for the initially negative results on presenteeism might 
be that employees who returned to work early were not 
completely fit and as productive as normally. In other 
words, there was an initial trade-off between reduced 
absenteeism and increased presenteeism. However, after 
the first 9 months, the additional costs caused by presen-
teeism ceased to exist and were reversed into benefits. 
This change is possibly driven by an improvement in 
quality of life when people work.
The literature suggests that in terms of economic costs, 
presenteeism often is a larger problem than absenteeism. 
Our results are not in line with these findings. This could 
be due to the Dutch system in which employees receive 
a substantial percentage of their wage during the first 
2 years of their illness. In many other countries, the fall in 
income is more acute when employees stay absent from 
their work, increasing the incentive to keep on working—
even when work is then associated with greater levels of 
presenteeism.
The results of our study can only be generalised to 
employees who have been sick-listed for 4–26 weeks, 
working in small- to medium-sized companies.
Conclusions and implications
In the Netherlands, employers have an incentive to 
invest in sickness management as they have the respon-
sibility to pay 70%–100% of the salary of sick-listed 
employees for up to 2 years. Employees who are on sick-
ness absence have to visit an occupational physician, 
paid by the employer within the first 6 weeks. Both the 
employee and employer have to agree on an action 
plan. In this plan, the responsibilities of both parties 
are defined to ensure a quick return to work of the 
employee. In this context, the ECO intervention can 
be seen as an effective intervention that, in addition, 
has a high probability of offering good value for money 
because the initial investment (of €300) is more than 
recouped within a single year as seen from the employ-
er’s perspective, while the employee derives benefits in 
the form of increased quality of life when returning to 
work sooner rather than later. As noted, some 95% CIs 
of our estimates are wide. By implication, one should 
not rely too much on the point estimates of net benefits, 
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ROI ratios, break-even points, because they lack preci-
sion. In other words, our estimates have some degree of 
uncertainty but suggest that the ECO intervention has a 
high likelihood to be an appealing business case as seen 
from most stakeholder perspectives.
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